Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1401-1409

  Wang, Mingyi ^a   Ma, Xiangdong ^b   Wang, Jian ^b   Wang, Lin ^b   Wang, Yu ^a  

^a The Chinese People's Liberation Army   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

secretase inhibitor; Cisplatin resistant cancer; DAPT; Hes1; Notch signaling; Notch1; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CASPASE 3; CISPLATIN; CYCLIN B1; DIPEPTIDE; HES1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; PROTEIN BCL 2; SECRETASE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CARCINOGENESIS; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; OVARY TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOGENESIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYCLIN B1; DIPEPTIDES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HOMEODOMAIN PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 84894448611     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2301     Document Type: Article

References (37)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. McGuire WP III and Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89 (Suppl 3): S3-S8, 2003.
3. Stewart JJ, White JT, Yan X, et al: Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5: 433-443, 2006.
4. Mellish KJ, Barnard CF, Murrer BA and Kelland LR: DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62: 717-723, 1995.
5. O'Neill CF, Koberle B, Masters JR and Kelland LR: Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 81: 1294-1303, 1999.
6. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H and Murata Y: Mechanisms of platinum drug resistance. Trends Pharmacol Sci 26: 113-116, 2005. (Pubitemid 40313588)
7. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
8. Meng RD, Shelton CC, Li YM, et al: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69: 573-582, 2009.
9. Kuroda Y, Murakami N, Morota M, et al: Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res 53: 588-593, 2012.
10. Lai EC: Notch signaling: control of cell communication and cell fate. Development 131: 965-973, 2004.
11. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999. (Pubitemid 29291335)
12. Nickoloff BJ, Osborne BA and Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-6608, 2003. (Pubitemid 37372340)
13. Suwannarurk K, Bhamarapravatana K, Thaweekul Y, Mairaing K, Poomtavorn Y and Pattaraarchachai J: A 1-year experience with liquid-based and conventional papanicolaou smear in Thammasat University Hospital. J Med Assoc Thai 94 (Suppl 7): S47-S51, 2011.
14. Wagner U, Marth C, Largillier R, et al: Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107: 588-591, 2012.
15. Doll CM, Aquino-Parsons C, Pintilie M, et al: The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. Int J Radiat Oncol Biol Phys 85: 721-727, 2013.
16. Miyamura T, Masuzaki H and Ishimaru T: Conservative treatment of a cervical pregnancy with local methotrexate injection. Int J Gynaecol Obstet 45: 62-63, 1994. (Pubitemid 24125618)
17. Rose SL, Kunnimalaiyaan M, Drenzek J and Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol Oncol 117: 130-133, 2010.
18. Chu D, Wang W, Xie H, et al: Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg 13: 253-260, 2009.
19. Wang M, Wang J, Wang L, Wu L and Xin X: Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Med Oncol 27: 1329-1335, 2010.
20. Yoo J, Choi JY, Moon SH, et al: Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer 22: 1226-1233, 2012.
21. Sorosky JI: Endometrial cancer. Obstet Gynecol 120: 383-397, 2012.
22. Wang M, Wu L, Wang L and Xin X: Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun 393: 144-149, 2010.
23. Hopfer O, Zwahlen D, Fey MF and Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93: 709-718, 2005. (Pubitemid 41486463)
24. Tsang RY, Al-Fayea T and Au HJ: Cisplatin overdose: toxicities and management. Drug Saf 32: 1109-1122, 2009.
25. Jones ME, van Leeuwen FE, Hoogendoorn WE, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 14: R91, 2012.
26. Ma K, Wen HW and Liao QP: Expression of Notch3 and Notch intracellular domain in ovarian carcinoma and effect of N-[N-(3,5-difluorophenyl) acetyl-L-alanyl]-S-phenyl glycine t-butyl ester on ovarian carcinoma cell. Zhonghua Fu Chan Ke Za Zhi 45: 921-926, 2010 (In Chinese).
27. Ma XG, Wang YM, Xue FX, et al: Clinicalpathological characteristics of Lynch syndrome related epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 47: 201-204, 2012 (In Chinese).
28. van den Akker T, Beltman J, Leyten J, et al: The WHO maternal near miss approach: consequences at Malawian District level. PLoS One 8: e54805, 2013.
29. Masuda S, Kumano K, Suzuki T, et al: Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci 100: 2444-2450, 2009.
30. Kohorn EI: Imaging practices in the diagnosis and management of gestational trophoblastic disease: an assessment. J Reprod Med 57: 207-210, 2012.
31. Sun XM, Wen HW, Chen CL and Liao QP: Expression of Notch intracellular domain in cervical cancer and effect of DAPT on cervical cancer cell. Zhonghua Fu Chan Ke Za Zhi 44: 369-373, 2009 (In Chinese).
32. Korsmeyer SJ: Regulators of cell death. Trends Genet 11: 101-105, 1995.
33. Drexler HC: Programmed cell death and the proteasome. Apoptosis 3: 1-7, 1998.
34. Ito M: Factors controlling cyclin B expression. Plant Mol Biol 43: 677-690, 2000.
35. Friedrich K, Wieder T, Von Haefen C, et al: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20: 2749-2760, 2001. (Pubitemid 32549832)
36. Williams J, Lucas PC, Griffith KA, et al: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295, 2005. (Pubitemid 40127123)
37. Beel AJ and Sanders CR: Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311-1334, 2008.